Understanding cognitive deficits in Parkinson's disease: Lessons from preclinical animal models

Learning and Memory

Volumn 20, Issue 10, 2013, Pages 592-600

  Solari, Nicola ^a   Bonito Oliva, Alessandra ^b   Fisone, Gilberto ^b   Brambilla, Riccardo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 [[2 (1 METHYL 2 PYRROLIDINYL)ETHYL]THIO]PHENOL; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; ALPHA SYNUCLEIN; ALTINICLINE; ANTIPARKINSON AGENT; DIZOCILPINE; DOPAMINE; DOPAMINE 3 RECEPTOR; LEVODOPA; N [4 [2 (8 CYANO 1,3A,4,9B TETRAHYDRO 1 BENZOPYRANO[3,4 C]PYRROL 2(3H) YL)ETHYL]PHENYL]ACETAMIDE; NORADRENALIN; OXIDOPAMINE; PRAMIPEXOLE; SEROTONIN;

ANIMAL MODEL; COGNITIVE DEFECT; COGNITIVMEMORY DISE DEFECT; DISEASE MODEL; EXECUTIVE FUNCTION; GENETIC MODEL; HUMAN; MAZE TEST; MEMORY DISORDER; MENTAL DETERIORATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIMATE; PRIORITY JOURNAL; REVIEW; RODENT; SUBSTITUTION THERAPY; WORKING MEMORY;

ANIMALS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; HUMANS; PARKINSON DISEASE;

EID: 84885092851     PISSN: 10720502     EISSN: 15495485     Source Type: Journal    
DOI: 10.1101/lm.032029.113     Document Type: Review

References (123)

1. Aarsland D, Ballard C, Rongve A, Broadstock M, Svenningsson P. 2012. Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia. Curr Neurol Neurosci Rep 12:492-501.
2. Abbott A. 2007. Neuroscience: The molecular wake-up call. Nature 447:368-370. (Pubitemid 46816715)
3. Abbott RD, Ross GW, White LR, Tanner CM, Masaki KH, Nelson JS, Curb JD, Petrovitch H. 2005. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 65:1442-1446. (Pubitemid 41552777)
4. Antal A, Bandini F, Keri S, Bodis-Wollner I. 1998. Visuo-cognitive dysfunctions in Parkinson's disease. Clin Neurosci 5:147-152. (Pubitemid 128751591)
5. Antonini A, Cilia R. 2009. Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: Incidence, neurobiological basis, management and prevention. Drug Saf 32:475-488.
6. Ballard CG, Aarsland D, McKeith I, O'Brien J, Gray A, Cormack F, Burn D, Cassidy T, Starfeldt R, Larsen JP, et al. 2002. Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 59:1714-1720. (Pubitemid 35424452)
7. Baunez C, Robbins TW. 1999. Effects of dopamine depletion of the dorsal striatum and further interaction with subthalamicnucleus lesions in an attentional task in the rat. Neuroscience 92:1343-1356. (Pubitemid 29292570)
8. Beal MF. 2001. Experimental models of Parkinson's disease. Nat Rev Neurosci 2:325-334.
9. Benazzouz A, Gross C, Feger J, Boraud T, Bioulac B. 1993. Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur J Neurosci 5:382-389. (Pubitemid 23108592)
10. Bevins RA, Besheer J. 2006. Object recognition in rats and mice: A one-trial non-matching-to-sample learning task to study 'recognition memory'. Nat Protoc 1:1306-1311.
11. Bezard E, Przedborski S. 2010. A tale on animal models of Parkinson's disease. Mov Disord 26:993-1002.
12. Bohnen NI, Albin RL. 2011. The cholinergic system and Parkinson disease. Behav Brain Res 221:564-573.
13. Bonito-Oliva A, Pignatelli M, Spigolon G, Yoshitake T, Seiler S, Longo F, Piccinin S, Kehr J, Mercuri NB, Nistico R, et al. 2013. Cognitive impairment and dentate gyrus synaptic dysfunction in experimental Parkinsonism. Biol Psychiatry (in press).
14. Bové J, Perier C. 2012. Neurotoxin-based models of Parkinson's disease. Neuroscience 211:51-76
15. Bowers D, Miller K, Mikos A, Kirsch-Darrow L, Springer U, Fernandez H, Foote K, Okun M. 2006. Startling facts about emotion in Parkinson's disease: Blunted reactivity to aversive stimuli. Brain 129:3356-3365. (Pubitemid 44871448)
16. Braak H, Braak E, Yilmazer D, De Vos RA, Jansen EN, Bohl J, Jellinger K. 1994. Amygdala pathology in Parkinson's disease. Acta Neuropathol 88:493-500. (Pubitemid 24364696)
17. Braak H, Del Tredici K, Rub U, De Vos RA, Jansen Steur EN, Braak E. 2003. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211. (Pubitemid 36007810)
18. Braga R, Kouzmine I, Canteras NS, Da Cunha C. 2005. Lesion of the substantia nigra, pars compacta impairs delayed alternation in a Y-maze in rats. Exp Neurol 192:134-141. (Pubitemid 40208546)
19. Bruck A, Kurki T, Kaasinen V, Vahlberg T, Rinne JO. 2004. Hippocampal and prefrontal atrophy in patients with early non-demented Parkinson's disease is related to cognitive impairment. J Neurol Neurosurg Psychiatry 75:1467-1469. (Pubitemid 39279819)
20. Carbon M, Marie RM. 2003. Functional imaging of cognition in Parkinson's disease. Curr Opin Neurol 16:475-480. (Pubitemid 36951824)
21. Chaudhuri KR, Odin P. 2010. The challenge of non-motor symptoms in Parkinson's disease. Prog Brain Res 184:325-341.
22. Chaudhuri KR, Schapira AH. 2009. Non-motor symptoms of Parkinson's disease: Dopaminergic pathophysiology and treatment. Lancet Neurol 8:464-474.
23. Chaudhuri KR, Healy DG, Schapira AH. 2006. Non-motor symptoms of Parkinson's disease: Diagnosis and management. Lancet Neurol 5:235-245. (Pubitemid 43238347)
24. Claassen DO, Josephs KA, Ahlskog JE, Silber MH, Tippmann-Peikert M, Boeve BF. 2010. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology 75:494-499.
25. Clark US, Neargarder S, Cronin-Golomb A. 2008. Specific impairments in the recognition of emotional facial expressions in Parkinson's disease. Neuropsychologia 46:2300-2309.
26. Cools R, Barker RA, Sahakian BJ, Robbins TW. 2001. Mechanisms of cognitive set flexibility in Parkinson's disease. Brain 124:2503-2512. (Pubitemid 33134938)
27. Costa A, Peppe A, Dell'Agnello G, Caltagirone C, Carlesimo GA. 2009. Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: Effects of pramipexole and pergolide on working memory. Neuropsychologia 47:1374-1381.
28. Costa C, Sgobio C, Siliquini S, Tozzi A, Tantucci M, Ghiglieri V, Di Filippo M, Pendolino V, De Iure A, Marti M, et al. 2012. Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease. Brain 135:1884-1899.
29. Cummings JL. 1992. Depression and Parkinson's disease: A review. Am J Psychiatry 149:443-454.
30. Da Cunha C, Gevaerd MS, Vital MA, Miyoshi E, Andreatini R, Silveira R, Takahashi RN, Canteras NS. 2001. Memory disruption in rats with nigral lesions induced by MPTP: A model for early Parkinson's disease amnesia. Behav Brain Res 124:9-18. (Pubitemid 32567554)
31. Da Cunha C, Wietzikoski S, Wietzikoski EC, Miyoshi E, Ferro MM, Anselmo-Franci JA, Canteras NS. 2003. Evidence for the substantia nigra pars compacta as an essential component of a memory system independent of the hippocampal memorysystem. Neurobiol Learn Mem 79:236-242. (Pubitemid 36379194)
32. De Leonibus E, Pascucci T, Lopez S, Oliverio A, Amalric M, Mele A. 2007. Spatial deficits in a mouse model of Parkinson disease. Psychopharmacology (Berl) 194:517-525. (Pubitemid 47492993)
33. De Leonibus E, Manago F, Giordani F, Petrosino F, Lopez S, Oliverio A, Amalric M, Mele A. 2009. Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease. Neuropsychopharmacology 34:729-738.
34. Decamp E, Schneider JS. 2006. Effects of nicotinic therapies on attention and executive functions in chronic low-dose MPTP-treated monkeys. Eur J Neurosci 24:2098-2104. (Pubitemid 44596189)
35. Decamp E, Schneider JS. 2009. Interaction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model. Brain Res 1262:109-114.
36. Decamp E, Tinker JP, Schneider JS. 2004a. Attention and executive function deficits in chronic low-dose MPTP-treated non-human primates. Eur J Neurosci 20:1371-1378. (Pubitemid 39233588)
37. Decamp E, Tinker JP, Schneider JS. 2004b. Attentional cueing reverses deficits in spatial working memory task performance in chronic low dose MPTP-treated monkeys. Behav Brain Res 152:259-262. (Pubitemid 38757896)
38. Diamond A, Goldman-Rakic PS. 1989. Comparison of human infants and rhesus monkeys on Piaget's AB task: Evidence for dependence on dorsolateral prefrontal cortex. Exp Brain Res 74:24-40. (Pubitemid 19035070)
39. Ding JB, Guzman JN, Peterson JD, Goldberg JA, Surmeier DJ. 2010. Thalamic gating of corticostriatal signaling by cholinergic interneurons. Neuron 67:294-307.
40. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, et al. 2007. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68:384-386. (Pubitemid 46184217)
41. Dowd E, Dunnett SB. 2005. Comparison of 6-hydroxydopamine-induced medial forebrain bundle and nigrostriatal terminal lesions in rats using a lateralised nose-poking task with low stimulus-response compatibility. Behav Brain Res 165:181-186. (Pubitemid 41565527)
42. Downes JJ, Roberts AC, Sahakian BJ, Evenden JL, Morris RG, Robbins TW. 1989. Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson's disease: Evidence for a specific attentional dysfunction. Neuropsychologia 27:1329-1343. (Pubitemid 20015615)
43. Dubois B, Pillon B. 1997. Cognitive deficits in Parkinson's disease. J Neurol 244:2-8. (Pubitemid 26413891)
44. Dujardin K, Defebvre L, Krystkowiak P, Degreef JF, Destee A. 2003. Executive function differences in multiple system atrophy and Parkinson's disease. Parkinsonism Relat Disord 9:205-211. (Pubitemid 36287153)
45. Dunnett SB, Lelos M. 2010. Behavioral analysis of motor and non-motor symptoms in rodent models of Parkinson's disease. Prog Brain Res 184:35-51.
46. Emborg ME. 2007. Nonhuman primate models of Parkinson's disease. Ilar J 48:339-355. (Pubitemid 350194367)
47. Eslamboli A, Romero-Ramos M, Burger C, Bjorklund T, Muzyczka N, Mandel RJ, Baker H, Ridley RM, Kirik D. 2007. Long-term consequences of human α-synuclein overexpression in the primate ventral midbrain. Brain 130:799-815. (Pubitemid 46410741)
48. Fernagut PO, Chesselet MF. 2004. α-Synuclein and transgenic mouse models. Neurobiol Dis 17:123-130.
49. Fornai F, Schluter OM, Lenzi P, Gesi M, Ruffoli R, Ferrucci M, Lazzeri G, Busceti CL, Pontarelli F, Battaglia G, et al. 2005. Parkinson-like syndrome induced by continuous MPTP infusion: Convergent roles of the ubiquitin-proteasome system and a-synuclein. Proc Natl Acad Sci 102:3413-3418. (Pubitemid 40328059)
50. Fox SH, Chuang R, Brotchie JM. 2009. Serotonin and Parkinson's disease: On movement, mood, and madness. Mov Disord 24:1255-1266.
51. Fox SH, Visanji N, Reyes G, Huot P, Gomez-Ramirez J, Johnston T, Brotchie JM. 2010. Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease. Can J Neurol Sci 37:86-95.
52. Freichel C, Neumann M, Ballard T, Muller V, Woolley M, Ozmen L, Borroni E, Kretzschmar HA, Haass C, Spooren W, et al. 2007. Age-dependent cognitive decline and amygdala pathology in α-synuclein transgenic mice. Neurobiol Aging 28:1421-1435. (Pubitemid 47081234)
53. Galvan A, Smith Y. 2011. The primate thalamostriatal systems: Anatomical organization, functional roles and possible involvement in Parkinson's disease. Basal Ganglia 1:179-189.
54. Gasbarri A, Sulli A, Innocenzi R, Pacitti C, Brioni JD. 1996. Spatial memory impairment induced by lesion of the mesohippocampal dopaminergic system in the rat. Neuroscience 74:1037-1044. (Pubitemid 26313347)
55. Gerlach M, Riederer P. 1996. Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man. J Neural Transm 103:987-1041. (Pubitemid 26383833)
56. Gevaerd MS, Takahashi RN, Silveira R, Da Cunha C. 2001. Caffeine reverses the memory disruption induced by intra-nigral MPTP-injection in rats. Brain Res Bull 55:101-106. (Pubitemid 32586809)
57. Girotti F, Soliveri P, Carella F, Piccolo I, Caffarra P, Musicco M, Caraceni T. 1988. Dementia and cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry 51:1498-1502. (Pubitemid 19026519)
58. Goetz CG, Emre M, Dubois B. 2008. Parkinson's disease dementia: Definitions, guidelines, and research perspectives in diagnosis. Ann Neurol 64(Suppl 2):S81-S92.
59. Goldman JG, Litvan I. 2011. Mild cognitive impairment in Parkinson's disease. Minerva Med 102:441-459.
60. Hansen C, Bjorklund T, Petit GH, Lundblad M, Murmu RP, Brundin P, Li JY. 2013. A novel a-synuclein-GFP mouse model displays progressive motor impairment, olfactory dysfunction and accumulation of a-synuclein-GFP. Neurobiol Dis 56 C: 145-155.
61. Heindel WC, Salmon DP, Shults CW, Walicke PA, Butters N. 1989. Neuropsychological evidence for multiple implicit memory systems: A comparison of Alzheimer's, Huntington's, and Parkinson's disease patients. J Neurosci 9:582-587. (Pubitemid 19069503)
62. Hsieh MH, Gu SL, Ho SC, Pawlak CR, Lin CL, Ho YJ, Lai TJ, Wu FY. 2010. Effects of MK-801 on recognition and neurodegeneration in an MPTP-induced Parkinson's rat model. Behav Brain Res 229:41-47.
63. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S. 1995. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Neurodegeneration 4:257-269.
64. Jankovic J. 2008. Parkinson's disease: Clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79:368-376. (Pubitemid 351441488)
65. Kehagia AA, Barker RA, Robbins TW. 2010. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol 9:1200-1213.
66. Kirik D, Bjorklund A. 2003. Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors. Trends Neurosci 26:386-392. (Pubitemid 36794555)
67. Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, Bjorklund A. 2003. Nigrostriatal a-synucleinopathy induced by viral vector-mediated overexpression of human a-synuclein: A new primate model of Parkinson's disease. Proc Natl Acad Sci 100:2884-2889. (Pubitemid 36297593)
68. Knowlton BJ, Mangels JA, Squire LR. 1996. A neostriatal habit learning system in humans. Science 273:1399-1402. (Pubitemid 26296530)
69. Kulisevsky J, Garcia-Sanchez C, Berthier ML, Barbanoj M, Pascual-Sedano B, Gironell A, Estevez-Gonzalez A. 2000. Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: A two-year follow-up studyof previously untreated patients. Mov Disord 15:613-626. (Pubitemid 30479613)
70. Laatu S, Revonsuo A, Pihko L, Portin R, Rinne JO. 2004. Visual object recognition deficits in early Parkinson's disease. Parkinsonism Relat Disord 10:227-233. (Pubitemid 38534616)
71. Lange KW, Robbins TW, Marsden CD, James M, Owen AM, Paul GM. 1992. L-DOPA withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology (Berl) 107:394-404.
72. Lee AC, Harris JP, Calvert JE. 1998. Impairments of mental rotation in Parkinson's disease. Neuropsychologia 36:109-114. (Pubitemid 28105202)
73. Lees AJ, Smith E. 1983. Cognitive deficits in the early stages of Parkinson's disease. Brain 106(Pt. 2):257-270. (Pubitemid 13098511)
74. Levin BE. 1990. Spatial cognition in Parkinson disease. Alzheimer Dis Assoc Disord 4:161-170. (Pubitemid 20292273)
75. Lindgren HS, Dunnett SB. 2012. Cognitive dysfunction and depression in Parkinson's disease: What can be learned from rodent models? Eur J Neurosci 35:1894-1907.
76. Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J, Mollenhauer B, Rodriguez-Oroz MC, Troster AI, Weintraub D. 2011. MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD-MCI. Mov Disord 26:1814-1824.
77. Maddox WT, Filoteo JV, Delis DC, Salmon DP. 1996. Visual selective attention deficits in patients with Parkinson's disease: A quantitative model-based approach. Neuropsychology 10(Pt. 2):197-218. (Pubitemid 26129029)
78. Magen I, Fleming SM, Zhu C, Garcia EC, Cardiff KM, Dinh D, De La Rosa K, Sanchez M, Torres ER, Masliah E, et al. 2012. Cognitive deficits in a mouse model of pre-manifest Parkinson's disease. Eur J Neurosci 35:870-882.
79. Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, et al. 2011. Passive immunization reduces behavioral and neuropathological deficits in an a-synuclein transgenic model of Lewy body disease. PLoS One 6:e19338.
80. Matison R, Mayeux R, Rosen J, Fahn S. 1982. "Tip-of-the-tongue" phenomenon in Parkinson disease. Neurology 32:567-570.
81. Matsumoto N, Minamimoto T, Graybiel AM, Kimura M. 2001. Neurons in the thalamic CM-Pf complex supply striatal neurons with information about behaviorally significant sensory events. J Neurophysiol 85:960-976. (Pubitemid 32147793)
82. McDonald RJ, White NM. 1994. Parallel information processing in the water maze: Evidence for independent memory systems involving dorsal striatum and hippocampus. Behav Neural Biol 61:260-270.
83. Millan MJ, Buccafusco JJ, Loiseau F, Watson DJ, Decamp E, Fone KC, Thomasson-Perret N, Hill M, Mocaer E, Schneider JS. 2010. The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. Int J Neuropsychopharmacol 13:1035-1051.
84. Minamimoto T, Hori Y, Kimura M. 2005. Complementary process to response bias in the centromedian nucleus of the thalamus. Science 308:1798-1801. (Pubitemid 40848010)
85. Minamimoto T, Hori Y, Kimura M. 2009. Roles of the thalamic CM-PF complex-basal ganglia circuit in externally driven rebias of action. Brain Res Bull 78:75-79.
86. Miyoshi E, Wietzikoski S, Camplessei M, Silveira R, Takahashi RN, Da Cunha C. 2002. Impaired learning in a spatial working memory version and in a cued version of the water maze in rats with MPTP-induced mesencephalic dopaminergic lesions. Brain Res Bull 58:41-47. (Pubitemid 34732994)
87. Moriguchi S, Yabuki Y, Fukunaga K. 2012. Reduced calcium/calmodulin- dependent protein kinase II activity in the hippocampus is associated with impaired cognitive function in MPTP-treated mice. J Neurochem 120:541-551.
88. Mouradian MM. 2002. Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology 58:179-185.
89. Mura A, Feldon J. 2003. Spatial learning in rats is impaired after degeneration of the nigrostriatal dopaminergic system. Mov Disord 18:860-871. (Pubitemid 37021160)
90. Muslimovic D, Post B, Speelman JD, Schmand B. 2005. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 65:1239-1245. (Pubitemid 41508217)
91. Owen AM. 2004. Cognitive dysfunction in Parkinson's disease: The role of frontostriatal circuitry. Neuroscientist 10:525-537. (Pubitemid 39546395)
92. Owen AM, James M, Leigh PN, Summers BA, Marsden CD, Quinn NP, Lange KW, Robbins TW. 1992. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain 115(Pt. 6):1727-1751. (Pubitemid 23054862)
93. Owen AM, Beksinska M, James M, Leigh PN, Summers BA, Marsden CD, Quinn NP, Sahakian BJ, Robbins TW. 1993. Visuospatial memory deficits at different stages of Parkinson's disease. Neuropsychologia 31:627-644. (Pubitemid 23225380)
94. Owen AM, Iddon JL, Hodges JR, Summers BA, Robbins TW. 1997. Spatial and non-spatial working memory at different stages of Parkinson's disease. Neuropsychologia 35:519-532. (Pubitemid 27144004)
95. Pessiglione M, Czernecki V, Pillon B, Dubois B, Schupbach M, Agid Y, Tremblay L. 2005. An effect of dopamine depletion on decision-making: The temporal coupling of deliberation and execution. J Cogn Neurosci 17:1886-1896.
96. Pifl C, Schingnitz G, Hornykiewicz O. 1991. Effect of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience 44:591-605.
97. Pillon B, Ertle S, Deweer B, Bonnet AM, Vidailhet M, Dubois B. 1997. Memory for spatial location in 'de novo' parkinsonian patients. Neuropsychologia 35:221-228. (Pubitemid 27090802)
98. Pillon B, Deweer B, Vidailhet M, Bonnet AM, Hahn-Barma V, Dubois B. 1998. Is impaired memory for spatial location in Parkinson's disease domain specific or dependent on 'strategic' processes? Neuropsychologia 36:1-9. (Pubitemid 28105191)
99. Porras G, Li Q, Bezard E. 2012. Modeling Parkinson's disease in primates: The MPTP model. Cold Spring Harb Perspect Med 2:a009308.
100. Pothakos K, Kurz MJ, Lau YS. 2009. Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration. BMC Neurosci 10:6.
101. Ray NJ, Strafella AP. 2012. The neurobiology and neural circuitry of cognitive changes in Parkinson's disease revealed by functional neuroimaging. Mov Disord 27:1484-1492.
102. Redgrave P, Rodriguez M, Smith Y, Rodriguez-Oroz MC, Lehericy S, Bergman H, Agid Y, De Long MR, Obeso JA. 2010. Goal-directed and habitual control in the basal ganglia: Implications for Parkinson's disease. Nat Rev Neurosci 11:760-772.
103. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. 2008. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 23:183-189; quiz 313. (Pubitemid 351311545)
104. Robbins TW, Arnsten AF. 2009. The neuropsychopharmacology of fronto-executive function: Monoaminergic modulation. Annu Rev Neurosci 32:267-287.
105. Sahakian BJ, Morris RG, Evenden JL, Heald A, Levy R, Philpot M, Robbins TW. 1988. A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson's disease. Brain 111(Pt. 3):695-718.
106. Sawada M, Imamura K, Nagatsu T. 2006. Role of cytokines in inflammatory process in Parkinson's disease. J Neural Transm Suppl 70:373-381. (Pubitemid 44622226)
107. Schneider JS. 1990. Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitivelyimpaired, motor asymptomatic monkeys. Brain Res 534:25-36.
108. Schneider JS, Pope-Coleman A. 1995. Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey. Neurodegeneration 4:245-255.
109. Schneider JS, Van Velson M, Menzaghi F, Lloyd GK. 1998. Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: Comparison with levodopa treatment. Ann Neurol 43:311-317. (Pubitemid 28113593)
110. Schneider JS, Tinker JP, Van Velson M, Menzaghi F, Lloyd GK. 1999. Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys. J Pharmacol Exp Ther 290:731-739. (Pubitemid 29344569)
111. Schneider JS, Tinker JP, Menzaghi F, Lloyd GK. 2003. The subtype-selective nicotinic acetylcholine receptor agonist SIB-1553A improves both attention and memory components of a spatial working memory task in chronic low dose 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridinetreated monkeys. J Pharmacol Exp Ther 306:401-406. (Pubitemid 36734398)
112. Schneider JS, Pioli EY, Jianzhong Y, Li Q, Bezard E. 2012. Levodopa improves motor deficits but can further disrupt cognition in a macaque parkinson model. Mov Disord 28:663-667.
113. Schrag A, Morley D, Quinn N, Jahanshahi M. 2004. Development of a measure of the impact of chronic parental illness on adolescent and adult children. The parental illness impact scale (Parkinson's disease). Parkinsonism Relat Disord 10:399-405. (Pubitemid 39299140)
114. Squire LR, Zola SM. 1996. Structure and function of declarative and nondeclarative memory systems. Proc Natl Acad Sci 93:13515-13522. (Pubitemid 26424150)
115. Sy HN, Wu SL, Wang WF, Chen CH, Huang YT, Liou YM, Chiou CS, Pawlak CR, Ho YJ. 2010. MPTP-induced dopaminergic degeneration and deficits in object recognition in rats are accompanied by neuroinflammation in the hippocampus. Pharmacol Biochem Behav 95:158-165.
116. Tadaiesky MT, Dombrowski PA, Figueiredo CP, Cargnin-Ferreira E, Da Cunha C, Takahashi RN. 2008. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 156:830-840.
117. Tanila H, Bjorklund M, Riekkinen P Jr. 1998. Cognitive changes in mice following moderate MPTP exposure. Brain Res Bull 45:577-582. (Pubitemid 28262597)
118. Tatton NA, Kish SJ. 1997. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine- treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 77:1037-1048.
119. Turle-Lorenzo N, Maurin B, Puma C, Chezaubernard C, Morain P, Baunez C, Nieoullon A, Amalric M. 2006. The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: Relevance for Parkinson's disease. J Pharmacol Exp Ther 319:914-923.
120. Ungerstedt U, Ljungberg T, Steg G. 1974. Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons. Adv Neurol 5:421-426.
121. Van Asselen M, Almeida I, Andre R, Januario C, Goncalves AF, Castelo-Branco M. 2009. The role of the basal ganglia in implicit contextual learning: A study of Parkinson's disease. Neuropsychologia 47:1269-1273.
122. Vazey EM, Aston-Jones G. 2012. The emerging role of norepinephrine in cognitive dysfunctions of Parkinson's disease. Front Behav Neurosci 6:48.
123. Wright MJ, Burns RJ, Geffen GM, Geffen LB. 1990. Covert orientation of visual attention in Parkinson's disease: An impairment in the maintenance of attention. Neuropsychologia 28:151-159. (Pubitemid 20102223)